EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)

Mineo Matsumoto iD, Joseph Ryan Polli iD, Suresh K Swaminathan, Kaushik Datta iD, Cris Kamperschroer, Marie C Fortin iD, Smita Salian-Mehta iD, Rutwij Dave iD, Zheng Yang iD, Payal Arora iD, Masanori Hiura, Mizuho Suzuki und 2 weitere

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3316 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Mineo Matsumoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Review Division, Pharmaceuticals and Medical Devices Agency (PMDA), Chiyoda-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Immunomodulating Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Administration of a new drug candidate in a first‐in‐human (FIH) clinical trial is a particularly challenging phase in drug development and is especially true for immunomodulators, which are a diverse and complex class of drugs with a broad range of mechanisms of action and associated safety risks. Risk is generally greater for immunostimulators, in which safety concerns are associated with acute toxicity, compared to immunosuppressors, where the risks are related to chronic effects. Current methodologies for FIH dose selection for immunostimulators are focused primarily on identifying the minimum anticipated biological effect level (MABEL), which has often resulted in sub‐therapeutic doses, leading to long and costly escalation phases. The Health and Environmental Sciences Institute (HESI) – Immuno‐Safety Technical Committee (ITC) organized a project to address this issue through two complementary approaches: (i) an industry survey on FIH dose selection strategies and (ii) detailed case studies for immunomodulators in oncology and non‐oncology indications. Key messages from the industry survey responses highlighted a preference toward more dynamic PK/PD approaches as in vitro assays are seemingly not representative of true physiological conditions for immunomodulators. These principles are highlighted in case studies. To address the above themes, we have proposed a revised decision tree, which expands on the guidance by the IQ MABEL Working Group (Leach et al . 2021). This approach facilitates a more refined recommendation of FIH dose selection for immunomodulators, allowing for a nuanced consideration of their mechanisms of action (MOAs) and the associated risk‐to‐benefit ratio, among other factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunomodulating AgentsHumansDrug DevelopmentDose-Response Relationship, DrugImmunologic FactorsRisk AssessmentAdvisory Committees

Substanzen

Immunomodulating AgentsImmunologic Factors

Autor:innen und Institutionen

  • Review Division, Pharmaceuticals and Medical Devices Agency (PMDA), Chiyoda-ku, Tokyo, Japan.
  • Pharmacokinetic Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, Massachusetts, USA.
  • Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Nonclinical Safety, Bristol-Myers Squibb, New Brunswick, New Jersey, USA.
  • Preclinical Safety, Sanofi, Cambridge, Massachusetts, USA.
  • Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, New Jersey, USA.

ORCID-Profile: Mineo Matsumoto, Joseph Ryan Polli, Kaushik Datta, Marie C Fortin, Smita Salian-Mehta, Rutwij Dave, Zheng Yang, Payal Arora, Jean Sathish

Zitieren

APA

Matsumoto, M., Polli, J. R., Swaminathan, S. K., Datta, K., Kamperschroer, C., Fortin, M. C., Salian-Mehta, S., Dave, R., Yang, Z., Arora, P., Hiura, M., Suzuki, M., Brennan, F. R., & Sathish, J. (2024). Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3316

Vancouver

Matsumoto M, Polli JR, Swaminathan SK, Datta K, Kamperschroer C, Fortin MC, et al. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC). Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3316

BibTeX
@article{Matsumoto2024,
  author = {Matsumoto, Mineo and Polli, Joseph Ryan and Swaminathan, Suresh K and Datta, Kaushik and Kamperschroer, Cris and Fortin, Marie C and Salian-Mehta, Smita and Dave, Rutwij and Yang, Zheng and Arora, Payal and Hiura, Masanori and Suzuki, Mizuho and Brennan, Frank R and Sathish, Jean},
  title = {Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3316}
}
Kostenlos starten →